Epigenetics of suicidal behavior by R. N. Mustafin, A. V. Kazantseva, R. F. Enikeeva, Yu. D. Davydova, S. B. Malykh, V. V. Viktorov, E. K. Khusnutdinova

“…The analysis of a brain obtained from suicide victims, representing a unique tool for the analysis of modified genomic processes, revealed a wide range of reprogramming patterns of DNA methylation in promoters of the genes of polyamine (OAZ1, OAZ2, AMD1, ARG2, SKA2), serotonergic (SLC6A4) and GABAergic (GABRA1) systems, HPA-axis (GR, NR3C1), tyrosine kinase (TrkB) receptors, brain-derived neurotrophic factor (BDNF). …”
Get full text

Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial by Christopher J. Swearingen, Jeyanesh R. S. Tambiah, Ismail Simsek, Heli Ghandehari, Sarah Kennedy, Yusuf Yazici

“…Abstract Introduction Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. …”
Get full text

Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors by Guihong Yang, Yimei Wang, Huimin Zhao, Ziyi Jiang, Shansong Zheng, Mingjing Ge, Meimei Si, Xiaoyan Kang

“…Abstract Iruplinalkib (WX‐0593), a selective oral ALK/ROS1 tyrosine kinase inhibitor, was approved in China as first‐line therapy for ALK‐positive non‐small‐cell lung cancer (NSCLC) and for the treatment of locally advanced or metastatic ALK‐positive NSCLC that has progressed following crizotinib therapy. …”
Get full text

Possibility of Using NO Modulators for Pharmacocorrection of Endothelial Dysfunction After Prenatal Hypoxia by Igor Belenichev, Olena Popazova, Oleh Yadlovskyi, Nina Bukhtiyarova, Victor Ryzhenko, Sergii Pavlov, Valentyn Oksenych, Oleksandr Kamyshnyi

“…Levels of sEPCR, Tie2 tyrosine kinase, VEGF-B, SOD1/Cu-Zn SOD, GPX4, and GPX1 in the heart’s cytosolic homogenate were assessed using ELISA. …”
Get full text

Secondary prevention of preeclampsia by Muhammad Ilham Aldika Akbar, Muhammad Ilham Aldika Akbar, Roudhona Rosaudyn, Khanisyah Erza Gumilar, Khanisyah Erza Gumilar, Renuka Shanmugalingam, Gustaaf Dekker, Gustaaf Dekker

“…Proton pump inhibitors (PPIs) have shown potential in lowering soluble FMS-like tyrosine kinase-1 (sFlt-1) levels and enhancing endothelial function, but clinical trials have been inconsistent. …”
Get full text

FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers by Yongchang Tang, Hong Wang, Jiankun Zhang, Chunhui Yang, Fei Xu, Yan Song, Tianen Li, Qiangbo Zhang

“…Abstract The crosstalk between cancers and the immune microenvironment plays a critical role in malignant progression. FMS-like tyrosine kinase 3 (FLT3) is a frequently mutated gene in acute myeloid leukemia (AML). …”
Get full text

Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma by Yuji Uehara, MD, Hiroki Izumi, MD, PhD, Tetsuro Taki, MD, PhD, Tetsuya Sakai, MD, PhD, Hibiki Udagawa, MD, PhD, Eri Sugiyama, MD, PhD, Shigeki Umemura, MD, PhD, Yoshitaka Zenke, MD, PhD, Shingo Matsumoto, MD, PhD, Kiyotaka Yoh, MD, PhD, Shoko Kubota, MD, PhD, Keiju Aokage, MD, PhD, Naoya Sakamoto, MD, PhD, Shingo Sakashita, MD, PhD, Motohiro Kojima, MD, PhD, Michiko Nagamine, MD, PhD, Yukio Hosomi, MD, PhD, Masahiro Tsuboi, MD, PhD, Koichi Goto, MD, PhD, Genichiro Ishii, MD, PhD

“…Introduction: Resistance to EGFR tyrosine kinase inhibitors is influenced by tumor-intrinsic and -extrinsic factors. …”
Get full text

Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection by Song Dong, PhD, Bingfa Yan, PhD, Si-Yang Liu, PhD, Xuan Gao, PhD, Hui-Zhao Hong, MD, Hong-Ji Li, MD, Wei Gao, PhD, Hong-Hong Yan, PhD, Si-Yang Maggie Liu, PhD, Hai-Yan Tu, PhD, Yi Pan, PhD, Qing Zhou, PhD, Xue-Ning Yang, PhD, Xue-Feng Xia, PhD, Xin Yi, PhD, Wen-Zhao Zhong, PhD, Yi-Long Wu, MD, Jia-Tao Zhang, PhD

“…Introduction: EGFR tyrosine kinase inhibitor (TKI) is the standard adjuvant treatment for patients with stages IB to IIIA EGFR-mutated NSCLC. …”
Get full text

Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma by Zhaosong Xue, Ming Yao, Kang Chen, Taiyun Huang, Jianjun Li, Jian Chen, Fei Huang, Yubin Huang, Xiaoyong Cai, Yihe Yan

“…Abstract  Combining local interventions with tyrosine kinase inhibitors (TKIs) plus anti-PD-1 antibodies in a triple therapy has demonstrated remarkable anti-tumor efficacy and facilitated conversion resection in patients with initially unresectable hepatocellular carcinoma (HCC). …”
Get full text

ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2 by Dan Li, Wenjie Zhang, Ruiheng Wang, Shufeng Xie, Yixin Wang, Wanxin Guo, Zixuan Huang, Chaoqun Lu, Liang Shan, Han Liu, Lifang Ma, Xumin Hou, Zhenshu Xu, Jiayi Wang

“…This study investigated the potential of combining receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeting CAR-T cells with ferroptosis inducers to promote ferroptosis of tumor cells and enhance anti-tumor efficacy. …”
Get full text

Molecular Alterations of KIT Oncogene in Gliomas by Ana L. Gomes, Jorge S. Reis-Filho, José M. Lopes, Olga Martinho, Maryou B. K. Lambros, Albino Martins, Fernando Schmitt, Fernando Pardal, Rui M. Reis

“…KIT, a class III receptor tyrosine kinase (RTK), is frequently involved in tumourigenic processes. …”
Get full text

Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis by Margaret Stalker, MD, Connor B. Grady, MPH, Alex Watts, MS, Wei-Ting Hwang, PhD, Krishna Chandrasekhara, MS, Fangdi Sun, MD, Geoffrey Liu, MD, Devalben Patel, MD, Jorge Nieva, MD, Amanda Herrmann, MD, Kristen Marrone, MD, Vincent K. Lam, MD, Vamsidhar Velcheti, MD, Stephen V. Liu, MD, Gabriela Liliana Bravo Montenegro, MD, William Tompkins, MD, Tejas Patil, MD, Jared Weiss, MD, Kelsey Leigh Miller, MD, William Schwartzman, MD, Jonathan E. Dowell, MD, Khvaramze Shaverdashvili, MD, PhD, Liza Villaruz, MD, Amanda Cass, PharmD, Wade Iams, MD, Dara Aisner, MD, PhD, Charu Aggarwal, MD, MD, D. Ross Camidge, MD, PhD, Lova Sun, MD, Melina E. Marmarelis, MD

“…The predominant first EGFR–tyrosine kinase inhibitor was erlotinib (65%) before 2018 and osimertinib (81%) after 2018. …”
Get full text

Vision Improvement after Osimertinib Treatment in Paraneoplastic Optic Neuropathy Associated with Lung Adenocarcinoma by Masaomi Kubota, Nobumasa Tamura, Takaaki Hayashi, Euido Nishijima, Haruhiko Yanagisawa, Akira Kojima, Tadashi Nakano

“…Herein, we describe the clinical course of an older adult patient with PON whose loss of vision improved after switching between epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatments for cancer. …”
Get full text

Preserved Expression of Skin Neurotrophic Factors in Advanced Diabetic Neuropathy Does Not Lead to Neural Regeneration despite Pancreas and Kidney Transplantation by František Saudek, Monika Cahová, Terezie Havrdová, Klára Zacharovová, Helena Daňková, Luděk Voska, Věra Lánská, Nurcan Üçeyler, Claudia Sommer

“…Compared to DM and HC groups, we found a significantly higher (p < 0.05–0.001) expression of NGF (nerve growth factor), NGFR (NGF receptor), NTRK1 (neurotrophic receptor tyrosine kinase 1), GDNF (glial cell-derived neurotrophic factor), GFRA1 (GDNF family receptor alpha 1), and GFAP (glial fibrillary acidic protein) in both transplant groups (Tx1 and Tx2). …”
Get full text

The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity by Daniela Di Lisi, Cristina Madaudo, Giulia Alagna, Marco Santoro, Ludovico Rossetto, Sergio Siragusa, Giuseppina Novo

“…Abstract Aims Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. …”
Get full text

Correlation between Apelin and Some Angiogenic Factors in the Pathogenesis of Preeclampsia: Apelin-13 as Novel Drug for Treating Preeclampsia and Its Physiological Effects on Place... by Reham Z. Hamza, Abdel Aziz A. Diab, Mansour H. Zahra, Ali K. Asalah, Suzan M. M. Moursi, Najah M. Al-Baqami, Fawziah A. Al-Salmi, Mai S. Attia

“…Moreover, serum apelin, placental growth factor (PLGF), vascular endothelial growth factor (VEGF), soluble fms-like tyrosine kinase-1 (sFlt-1), soluble endoglin (sEng), interferon-gamma (IFN-γ), and interleukin-10 (IL-10) levels and serum superoxide dismutase enzyme (SOD) and catalase (CAT) activities of all groups were estimated at the end of experiment. …”
Get full text

Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States by Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin, Eric Q. Wu, Pallavi Patwardhan

“…**Background:** Despite advances in tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia in chronic phase (CML-CP), a sizeable proportion of patients with CML-CP remains refractory or intolerant to these agents. …”
Get full text

Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs. by Pakorn Prakaikietikul, Pattraporn Tajarenmuang, Phumiphat Losuriya, Natee Ina, Thanika Ketpueak, Thanat Kanthawang

“…<h4>Purpose</h4>To identify non-cancerous factors from baseline CT chest affecting survival in advanced non-small cell lung cancer (NSCLC) treated with first-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs).<h4>Methods</h4>Retrospective study of 172 advanced NSCLC patients treated with first-generation EGFR-TKIs as a first-line systemic treatment (January 2012 to September 2022). …”
Get full text

De Novo Acute Myeloid Leukemia with Combined CBFB-MYH11 and BCR-ABL1 Gene Rearrangements: A Case Report and Review of Literature by Venkata Rakesh Sethapati, Ra’ed Jabr, Leyla Shune, Wissam El Atrouni, Patrick R. Gonzales, Wei Cui, Shivani Golem

“…The detection of t(9;22) led to the addition of daily doses of dasatinib (tyrosine kinase inhibitor) from day 7 onwards. The patient achieved complete remission on day 45. …”
Get full text

Conventional type 1 dendritic cells in the lymph nodes aggravate neuroinflammation after spinal cord injury by promoting CD8+ T cell expansion by Li-Qing Wang, Xiao-Yi Wang, Yue-Hui Ma, Heng-Jun Zhou

“…In vivo, the fms-like tyrosine kinase 3 (Flt3) inhibitor quizartinib was administered to deplete cDC1s, while intraperitoneal injection of recombinant Flt3L and immunosuppressive drug FTY-720 was used to expand cDC1s and prevent T cell egress from lymph nodes (LNs), respectively. …”
Get full text